A Phase 1/2 interventional study of Tobramycin in Cystic Fibrosis, sponsored by University Medical Center Groningen. Status unknown at 1 site in Netherlands. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-10-01.
Sponsored by University Medical Center Groningen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing tobramycin in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. Tobramycin · Cystic Fibrosis.
Among the 25 studies testing tobramycin in Cystic Fibrosis, this one is the 22nd largest by planned enrollment, is the only one that started in 2019, is one of 2 in phase 1/2, and was the 25th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 25 studies testing tobramycin in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
Tobramycin: first FDA approval 1975 (NEBCIN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 10 · Phase 4 5
First in 1995; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 55 across the 25 interventional studies. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 25 have an industry lead sponsor. The 10 most frequent:
University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 175 are open to participants now.
University Medical Center Groningen has 3 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing tobramycin in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal is to investigate the pharmacokinetic properties of dry powder tobramycin via the Cyclops® at different dosages in children with cystic fibrosis, together with the local tolerability.
Rationale: Cystic fibrosis is the most common life-shortening autosomal recessive disease among Caucasian populations. It is a chronic progressive disease causing deterioration of pulmonary function, and of general condition as well. Although it is a multisystem disease, the primary cause of death is respiratory failure, resulting from chronic pulmonary infection.
Pseudomonas aeruginosa is the predominant pathogen. The presence of P. aeruginosa in patients with CF is an unfavourable prognostic indicator and is associated with accelerated lung tissue destruction and loss of lung function, subsequently leading tot increased morbidity and mortality. Preventing, limiting and treating chronic infection with P. aeruginosa is therefore crucial in the management of CF, to improve survival and quality of life.
Currently most children with CF who are colonized with P. aeruginosa receive inhaled tobramycin every other month, mostly by use of a nebulizer. This delivery system however has several disadvantages. For example, the nebulisation itself and the cleaning of the nebulizer is time consuming. This places a high burden on a CF patient, especially for children, which will negatively influence compliance and quality of inhalation, thereby jeopardizing effective treatment. Therapy with a (disposable) dry powder inhaler (DPI) is less time consuming. Besides this, nebulisation brings the risk of auto-re-infection of the patient (contamination of nebulisation fluid and/or device). Other more technical disadvantages of nebulisation are a low lung deposition and pollution with tobramycin in the surrounding environment. With an efficient DPI, a three to six fold higher lung deposition compared to a nebulizer can be obtained. Nebulised tobramycin is used most in routine care, but sometimes a DPI is used, for example the Podhaler®. Although the dispersion behaviour of these dry powder systems is often good, the engineering processes make the products expensive, and the high excipient fractions make the inhaled powder doses high. Furthermore because these devices are not disposable, there is a risk of bacterial resistance development in the device. Next to this is the hygroscopic nature of tobramycin a risk for good dispersion when a used DPI is store inappropriately. In this situation powder residues in the inhaler become sticky or even liquefied when they absorb moisture from the air. There is one disposable DPI for tobramycin available, called the Cyclops®, but this DPI is not registered for children with CF yet. The investigators will therefore investigate dry powder tobramycin (DP tobramycin) in the Cyclops® in children with CF.
Objective: The main objectives are to investigate the pharmacokinetic properties of DP tobramycin via the Cyclops® at different dosages in children with CF, together with the local tolerability.
Study design: Single center, single ascending, single dose study.
Study population: 10 patients with CF, age 6 - 18 years.
Main study parameters/endpoints: The following pharmacokinetic parameters will be calculated: actual dose (dose minus remainder in inhaler after inhalation), AUC0-12 (area under the curve from 0 - 12 h), Cmax (maximum plasma concentration), Tmax (time to maximum plasma concentration), Ka (absorption rate constant), T1/2 el (terminal elimination half-life), CL/F (clearance following pulmonary administration (F= bioavailability)). Local tolerability of DP Tobramycin is determined by scoring adverse events, specifically coughing, and lung function measurement.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Target population of this study consists of children aged 6-18 years, because no information is available for inhalation of tobramycin using the Cyclops® in this population. Moreover, especially for children with CF a more easy to use and less time consuming treatment may improve their quality of life. Children participating in this study will receive instructions before using the DPI and their inspiratory flow will be tested. After each test dose serum samples will be collected with dry blood spot via a finger prick. To investigate safety, lung function tests will be performed before and 15, 30 and 90 minutes after inhalation and the occurrence of adverse events will be scored. Tobramycin is a registered drug for the treatment of chronic P. aeruginosa infection in CFpatients of 6 years and older. Inhalation of tobramycin is proven to be effective and safe in multiple studies. Dry powder tobramycin inhalation via the Cyclops® has been evaluated in adults with non-CF bronchiectasis. In this study a good drug dose - serum concentration correlation was obtained in adults, and the dry powder tobramycin inhalation via the Cyclops has been found safe with only mild tobramycin-related cough was reported once.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
Drug: Tobramycin
Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
Also known as: Tobramycin dry powder
AUC 0-12
Area under the curve from 0 - 12 h
Time frame: 0-12 hours after dry powder inhalation
Cmax
maximum plasma concentration
Time frame: 0-12 hours after dry powder inhalation
Tmax
Time to maximum plasma concentration
Time frame: 0-12 hours after dry powder inhalation
Ka
Absorption rate constant
Time frame: 0-12 hours after dry powder inhalation
T 1/2 el
Terminal elimination half-life
Time frame: 0-12 hours after dry powder inhalation
CL/F
Clearance following pulmonary administration
Time frame: 0-12 hours after dry powder inhalation
Local tolerability
Local tolerability determined by scoring adverse events, specifically coughing, and lung function
Time frame: Before and 15, 30 and 90 minutes after inhalation
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2019 to primary completion in Nov 2020, 17 months.
Of 26 phase 1/2 interventional studies under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tobramycin
University Medical Center Groningen →